Sarepta Therapeutics (SRPT) shares are getting crushed after a series of analyst downgrades on the heels of an FDA request to stop its Elevidys treatment. Rachel Dashiell diagnoses the biotech company's technical patterns taking shape on the chart. For the short-term chart, she sees resistance around $17 amid a strong downtrend. On the longer 15-year timeframe, Rachel says the 200-day moving average has acted as long term support for about 7 years around the $120 point.